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Background: The inhibitor of apoptosis (IAP) protein Survivin and its splice variants are differentially expressed in
breast cancer tissues. Our previous work showed Survivin is released from tumor cells via small membrane-bound
vesicles called exosomes. We, therefore, hypothesize that analysis of serum exosomal Survivin and its splice variants
may provide a novel biomarker for early diagnosis of breast cancer.
Methods: We collected sera from forty breast cancer patients and ten control patients who were disease free
for 5 years after treatment. In addition, twenty-three paired breast cancer tumor tissues from those same 40
patients were analyzed for splice variants. Serum levels of Survivin were analyzed using ELISA and exosomes
were isolated from this serum using the commercially available ExoQuick kit, with subsequent Western blots
and immunohistochemistry performed.
Results: Survivin levels were significantly higher in all the breast cancer samples compared to controls (p < 0.05)
with exosome amounts significantly higher in cancer patient sera compared to controls (p < 0.01). While Survivin
and Survivin-ΔEx3 splice variant expression and localization was identical in serum exosomes, differential expression of
Survivin-2B protein existed in the exosomes. Similarly, Survivin and Survivin-ΔEx3 proteins were the predominant forms
detected in all of the breast cancer tissues evaluated in this study, whereas a more variable expression of Survivin-2B
level was found at different cancer stages.
Conclusion: In this study we show for the first time that like Survivin, the Survivin splice variants are also
exosomally packaged in the breast cancer patients’ sera, mimicking the survivin splice variant pattern that we also
report in breast cancer tissues. Differential expression of exosomal-Survivin, particularly Survivin-2B, may serve as
a diagnostic and/or prognostic marker, a “liquid biopsy” if you will, in early breast cancer patients. Furthermore,
a more thorough understanding of the role of this prominent antiapoptotic pathway could lead to the development
of potential therapeutics for breast cancer patients.
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Breast cancer is the most common cancer among
women in the United States, and is the main cause of
death in women 45 to 55 years of age with an estimated
226,870 new cases of invasive breast cancer expected to
occur among women in the US this year [1,2]. The* Correspondence: nwall@llu.edu
1Department of Biochemistry, Loma Linda University School of Medicine,
Loma Linda, CA, USA
2Center for Health Disparities & Molecular Medicine, Loma Linda University
School of Medicine, 11085 Campus Street, Mortensen Hall Room 160, Loma
Linda, CA 92350, USA
Full list of author information is available at the end of the article
© 2014 Khan et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orultimate outcome of breast cancer relies on its initial
stage at diagnosis with the main prognostic factors asso-
ciated with breast cancer being lymph node involvement,
tumor size and histological grade [3]. However, tumor at
the same stage can behave in a different manner, and the
prognosis can vary [4]. Therefore, it is important to find
biomarkers that will predict the likelihood of recurrence
and identify those patients who might benefit from add-
itional therapy. Hence, low-risk patients can be spared
unnecessary and costly treatment. Moreover, high-risk
patients could be rapidly identified and offered appropri-
ately aggressive treatment.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the regulation of mitosis in cancer cells. Survivin is over-
expressed in a wide spectrum of tumors including pros-
tate, pancreas, lung, ovarian, and breast cancer [5,6].
Recently, survivin expression in human breast cancers has
been found using RT-PCR [7,8]. Like many genes, survivin
is alternatively spliced with a number of new splice
variants. Among them, survivin-2B is characterized by
introducing a new exon of 69 bp with proapoptotic
activity. Survivin-ΔEx3 has exon 3 excluded, and like the
wild type, carries antiapoptotic activity. Survivin-3B has
inclusion of a part of intron 3, preserving a complete BIR
domain with antiapoptotic activity. Survivin-2α, the
smallest survivin transcript, includes a 197 bp region of
the 3′ end of intron 2, resulting in a truncated version of
the BIR domain also having proapoptotic function [9,10].
Survivin and its splice variants are found to be associated
with aggressive phenotypes of cancers [11] and may, if not
prognostic, one day be considered like Her2 and hormone
receptor to be predictive variables of breast cancer [3].
Survivin was recently shown to be released from can-
cer cells to the tumor microenvironment via small mem-
brane bound vesicles (50-100 nm) called exosomes [12].
There has also been demonstrated a strong association
of exosomal Survivin with high-risk prostate cancers
(Gleason 6 and 9) as well as in cases becoming resistant
to chemotherapy [13]. Although Survivin and its splice
variants were shown differentially expressed in breast
cancer tissues and were correlated with aggressiveness
[6], their exosomal existence has not yet been addressed.
Tumor-derived exosomes play multiple roles in tumor
growth and metastasis and may produce their functions
by influencing immune escape, tissue invasion and angio-
genesis [14]. We have therefore undertaken the analysis of
exosomal Survivin and its splice variants in breast cancer
patient sera in parallel with paired breast tumor tissue.
We believe exosomal investigation may provide novel bio-
markers for early diagnosis of breast cancer when added
to current recommended methods. Although Survivin and
Survivin-ΔEx3 were detected in all of the samples
examined, Survivin-2B was differentially expressed
depending on the disease aggressiveness. Exosomal
Survivin-2B (proapoptotic) was expressed mostly in pri-
mary tumors in early stage disease, whereas low or no
expression was found in high-grade tumors. Survivin-
2B was absent in most distant metastasis. We therefore
believe that exosomal Survivin-2B can be further inves-




Serum samples were collected from forty breast cancer
patients, ages ranging from 34-85 (median age 54) withclinical staging I-IV. Ten control samples from females
who had undergone neoadjuvant treatment with either
Zometa, Anastrazole, Taxol, Gemcitabine, Carboplatin
and/or TCH followed by surgery with no recurrence
were selected as controls. From the original 40 samples,
23 paired tissue and serum samples were obtained
for splice variant analysis. All samples were collected
through the San Manuel Band of Mission Indians Bios-
pecimen Laboratory and the Cancer Center at Loma
Linda University. Blood was collected in vacuum tubes
containing sodium heparin. The tubes were centrifuged
at 2000 × g for 7 minutes, and the serum was then re-
moved and aliquoted for storage at -80°C.
Patient consent
Written informed consent was sought and obtained
from all participants involved in the course of these
Loma Linda University Adventist Health Sciences IRB-
approved studies in accordance with Loma Linda Uni-
versity policy.
Human survivin immunoassay
Serum sample Survivin concentrations were quantitated
using a commercially available human Survivin Immuno-
assay kit (R&D systems, Minneapolis, MN) according to
the manufacturer’s instructions.
Exosome isolation
For serum samples, the commercially available ExoQuick
kit (SBI, Mountain View, CA) was employed. In brief,
100 μl of serum was incubated with 100 μl of ExoQuick
solution followed by 2 hours incubation at 4°C followed
by centrifugation at 1500 × g for 30 minutes. After cen-
trifugation, the exosomes appear as a white pellet at the
bottom of the vessel, which was then reconstituted with
500 μl of dH2O (Sigma, St. Louis, MO).
Exosome quantification
To quantify the amount of exosomes released, we
assessed the activity of acetylcholinesterase, an enzyme
that is associated with these vesicles. Acetylcholinester-
ase activity was performed as described by Savina et al
[15]. Briefly, 40 μl of the exosome fraction was sus-
pended in 110 μl of PBS. 37.5 μl of this PBS-diluted exo-
some fraction was added to individual wells on a 96-well
flat-bottomed microplate. Acetylthiocholine (1.25 mM)
and 0.1 mM 5,50-dithiobis (2-nitrobenzoic acid) were
then added to exosome fractions in a final volume of
300 μl, and the change in absorbance at 412 nm was
monitored every 5 minutes for 30 minutes.
Western blot analysis
For Western blot analysis, cells or exosomal prepara-
tions were lysed using lysis buffer (50 mM Tris (pH 7.5),
Khan et al. BMC Cancer 2014, 14:176 Page 3 of 9
http://www.biomedcentral.com/1471-2407/14/1761% NP40, 0.25% DOC, 150 mM NaCl2, 1 mM PMSF, 10
μg/ml aprotinin/leupeptin/pepstatin, 20 mM NaF, 0.2
mM EGTA, 1 mM EDTA (pH 8.0), H2O). For protein
concentrations, the BCA assay (Pierce, Rockford, IL) was
used. Proteins from exosomes (20-40 μg) were separated
using 12% Bis-Tris polyacrylamide gels, transferred onto
polyvinylidene difluoride membranes (Millipore, Billerica,
MA) and probed using the following antibodies: mouse
monoclonal anti-LAMP1 (Abcam, Cambridge, MA), Anti-
Survivin-2B, Anti-Survivin-ΔEx3 (Cell Signaling, Danvers,
MA), and rabbit polyclonal anti-Survivin (Novus, Littleton,
CO). Secondary antibodies (IR-Dye conjugated) were goat
anti-rabbit and goat anti-mouse immunoglobulin (LICOR,
Lincoln, NE). Immunoreactive bands were detected using
the Odyssey Imaging System (LICOR, Lincoln, NE) and
quantified using ImageQuant software.Immunohistochemistry
Pathological diagnosis of receptor status was performed
by immunostaining for ER, PR, and Her2 as routine
pathological procedures. Formalin fixed paraffin embed-
ded tissues were cut into 4 micron sections. The detailed
deparaffinization and immunohistochemistry protocols
have been described previously [16]. Briefly, slides were
stained using the commercially available anti-Survivin,
Survivin-2B, and Survivin-ΔEx3 antibodies. Staining was
performed manually in the following manner. Slides
were deparaffinized through xylene and graded ethyl al-
cohol and then rinsed in water. Antigen retrieval was
performed by boiling slides in antigen retrieval solution
(Dako, Carpinteria, CA; pH 6.0) in a microwave oven at
maximum power for 4 minutes and at half maximum
power for 12 minutes, followed by a 30 minute cool-
down and rinsing in wash buffer. Slides were then
sequentially treated with the following reagents in a
humidified chamber at room temperature: 10% normal
goat serum for 30 minutes, anti-Survivin/-2B/-ΔEx3
antibody (1:100 dilution) overnight, and secondary anti-
body conjugated with Alexa Fluor 555 and 488 for 30
minutes for signal amplification. Nuclear staining was
performed using DAPI containing mounting media for
5 minutes. Stained slides were analyzed for Survivin/-
2B/-ΔEx3 antibody expressions.Image acquisition using laser-scanning confocal
microscopy
Stained tumor tissues were imaged and analyzed with an
Olympus FV 1000 laser scanning confocal imaging system
mounted onto an Olympus 1×81 microscope (Olympus
America Inc., PA). Microscopic data was acquired with a
20x objective lens. Staining intensities were confirmed by
two investigators, working independently, including a
pathologist.Statistical analysis
All comparisons for statistical significance were performed
using a Student t test, with all p values representing
two-tailed tests. Statistical software (Simple Interactive
Statistical Analysis) was used. A value of P < 0.05 was
considered statistically significant.
Results
Detection of survivin in cancer patient sera
Survivin protein levels as detected by ELISA were sig-
nificantly (*p < 0.05) higher in cancer patient sera com-
pared to controls (Figure 1A). Out of forty patient
samples examined, 95% had moderate to high serum
levels of Survivin. We also correlated Survivin levels
from 2 patients sera obtained before and after treatment
as shown in Figure 1B. Out of forty patient samples ex-
amined, 95% had moderate to high serum levels of Sur-
vivin. Serum Survivin was next correlated with tumor
stage (Table 1). In Stage II/III and IV disease, moderate
to high levels of Survivin were detected in 94% and 86%
of total cases, respectively. No significant difference was
detected in these stages. We next examined the serum
level of Survivin in the context of patient hormone recep-
tor status. Moderate to high serum levels of Survivin were
detected in 86% of triple negative (ER-PR-Her2-) breast
cancer, and 83% of patients with ER and PR positive, Her2
negative (ER + PR +Her2-) receptor status (Table 2).
Exosomes and exosomal survivin splice variants in breast
cancer patient sera
Exosomal analysis using the semiquantitative acetylcholin-
esterase activity assay showed that in sera taken from breast
cancer patients (n = 40), cancer exosome amount is signifi-
cantly (**p < 0.01) higher compared to exosome amounts in
serum from control patients (n = 10) (Figure 2A).
Exosomes were also evaluated using Western blotting
(Figure 2B) for the packaging of Survivin and its splice vari-
ant contents followed by densitometric analysis (Figure 2C)
of all samples (N = 40). By densitometry, Survivin and
Survivin-ΔEx3, using LAMP1 as the internal standard,
were uniformly elevated in all patient exosomes. However,
Survivin-2B, again standardized using LAMP1, was lower
than Survivin and Survivin-ΔEx3 protein obtained from
the same exosomes examined.
Survivin-2B is differentially expressed in breast cancer
tissues
Survivin, Survivin-ΔEx3, and Survivin-2B expression and
tumor grade is summarized in Table 3. Staining intensity
was described as absent staining (0), low (+), moderate
(++) and high (+++). In stage II/III disease, moderate
(++) to high expression (+++) of Survivin was found in
89% and 94% in stage IV (metastasis) tumors. Similarly,
moderate (++) to high (+++) Survivin-ΔEx3 expression
Figure 1 Survivin quantification in patient sera. (A) Survivin ELISA in control (with no recurrence after initial treatment) and breast cancer
patients’ sera. Survivin level was compared with active breast cancer cases (n = 40) to controls (n = 10). Survivin values less than 50 pg/mL were
considered normal while a Survivin level of 50-70 pg/mL was considered mild, 70-90 pg/mL moderate and >90 pg/mL as high. (*p < 0.05)
(B) Treatment may affect patient sera Survivin levels. In two patients (patient#1), (patient#2) serum Survivin level are measured before and
one year after treatment. (Error bar = Mean+/-SD). (BC, breast cancer).
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IV disease. Conversely, Survivin-2B expression was low
to absent in 75% of stage II/III diseases and absent
in 100% of Stage IV diseases. For each type of breast
tissue investigated, Survivin (Figure 3A & D) and
Survivin-ΔEx3 (Figure 3B & E) were the predominant
forms detected. Survivin-2B expression (Figure 3 C & F)
was low in the tumor tissues examined.Table 1 Relationship of serum survivin with clinical
staging
Survivin ELISA Stage II/III Stage IV
Moderate to high (70 pg/ml) 17 (94%) 19 (86%)
Low normal to mild (<50 pg/ml) 1 (6%) 3 (14%)
Total 18 22In the early stages of the breast cancer tissues we in-
vestigated, comparable expression of both Survivin and
Survivin-2B (Figure 4A & 4B) was detected (Stage I). Al-
though Survivin (Figure 4C) was strongly expressed in
triple negative (ER-PR-Her2-) tumor tissues, Survivin-2B
was absent (Figure 4D). In high-grade tumor tissue
showing stronger Survivin expression (Figure 4E), low or
no expression of Survivin-2B was recorded (Figure 4F).Table 2 Correlation of serum survivin levels with
receptor status




ER + PR +
Her2+
Moderate to high (70 pg/ml) 19 (83%) 6 (86%) 1 (50%)
Low normal to mild (<50 pg/ml) 4 (17%) 1 (14%) 1 (50%)
Total 23 7 2
Figure 2 (See legend on next page.)
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Figure 2 Exosome level and exosomal contents from patient sera. (A) Acetylcholinesterase Activity Assay: exosomes quantity was shown in
the graph from sera of breast cancer patients (n = 40) with controls (n = 10) (**p < 0.01) (BC, breast cancer). (B) Western blot analysis of all
exosomal Survivin, Survivin-2B, Survivin-ΔEx3, and LAMP1 from breast cancer patients sera (n = 40). (C) Densitometric analysis of Survivin,
Survivin-2B, Survivin-ΔEx3, and LAMP1 expression was performed. A ratio of each Survivin variant to LAMP1 was calculated and depicted in the
graph (error bar =mean +/- SD).
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in high-grade breast cancer tissues (Figure 5A-5C) and
stage IV distant metastasis (Figure 5D-5F). Both proteins
when colocalized are shown as a yellow staining pattern
in the composites (Figure 5C and 5F). Although Survi-
vin and Survivin-ΔEx3 proteins were predominantly
expressed in cancer tissues, and distant metastasis, they
were expressed in different grades of the tumor and ex-
pression pattern was similar in breast cancer tissues with
different receptor status. However, an inverse correlation
of Survivin-2B with tumor grade was recorded in these
cancer tissues. A strong correlation with Her2-negativity
with low or no Survivin-2B expression was also re-
corded. Minimal expression of Survivin-2B was found in
normal adjacent tissues with no expression of Survivin
or Survivin-ΔEx3 (data not shown).
Discussion
Survivin has been recognized as an important molecular
marker and target in a variety of cancer prognoses and
therapeutics [17-19]. We have recently reported exosomal
Survivin in the conditioned media (CM) from a number of
cancer cell lines and in serum acquired from patients with
prostate cancer [13]. This however, is the first report
of Survivin and its splice variants Survivin-ΔEx3 and
Survivin-2B in exosomes purified from breast cancer
serum samples. In addition, the evaluation of this import-
ant family of apoptosis regulators in the treatment and
understanding of breast cancer is also quite novel. Inter-
action of Survivin with its splice variants and the subcellu-
lar location where these interactions take place are crucial
for validating Survivin as a target for cancer therapeutics,
prognosis and probable prediction. Development of newTable 3 Relationship between expressions of survivin and
its splice variants in tissues with clinical staging
Characteristic n Survivin Survivin-2B Survivin-ΔEx3
Stage II/III 7 +++ (62%) +++ (0%) +++ (50%)
++ (27%) ++ (25%) ++ (50%)
+ (11%) + (50%) + (0%)
0 (0%) 0 (25%) 0 (0%)
Stage IV 9 +++ (75%) +++ (0%) +++ (70%)
++ (19%) ++ (0%) ++ (25%)
+ (6%) + (19%) + (5%)
0 (0%) 0 (81%) 0 (0%)model systems may be desired to unravel the mechanism
for the functions of Survivin and its variants in tumorigen-
esis. In this work we have not yet fully identified the sub-
cellular location of these Survivin splice variants, only the
exosomal pool.
Currently, there is no strong evidence suggesting that
Survivin splice variants are involved in tumorigenesis [20].
In this study, we evaluate the localization of Survivin and
its splice variants in exosomes from breast cancer patients.
We show that Survivin can coexist and possibly colocalize
with its alternatively spliced protein products in the tumor
tissues as well as in exosomes. This change in localization
suggests the possibility of functionally distinct Survivin
complexes that may arise within tumor cells that aber-
rantly express Survivin proteins at high levels. Import-
antly, the expression patterns observed in exosomes
precisely mimic the patterns observed in tumor tissue.
Currently there is rigorous research ongoing in the field
of tumor biomarker discovery with exosomes playing an
important role there [21,22]. Exosomal Survivin and
Survivin splice variant measurement could serve as reli-
able biomarkers for the purpose of early diagnosis.
Although our current study is limited to stage II-IV
patient populations, it may be of great interest to explore
the diagnostic value of this novel tumor marker in stage
I invasive breast cancer and ductal carcinoma in situ in
the future. The exosomal packaging may suggest the
possibility of functionally distinct Survivin and Survivin
splice variants within tumor cells that aberrantly express
high levels of these Survivin proteins. We suggest that
targeting specific Survivin isoforms, rather than Survivin
alone, may selectively and effectively destroy tumor cells.
Recently, Caldas et al., reported that survivin-ΔEx3 and
survivin-2B can heterodimerize with survivin DNA and
alter its subcellular localization [9]. Islam et al., reported
that the expression of survivin-2B is predominant in some
neuroblastomas with good prognosis, but it is expressed at
low levels in most malignant tissues [23]. In our study, we
found that Survivin-2B expression was inversely related to
tumor grade in breast cancer patient tissues or exosomes
compared to Survivin and Survivin-ΔEx3.
Early stage breast cancer showed expression of Survivin-
2B, but there was low or no expression detected in the
later stages of the tumors. In patients whose Survivin-2B
expression responded well to treatment, we are following
up to correlate the role of Survivin-2B expression with
good prognosis, as Survivin-2B seems to act as a natural
Figure 3 Immunohistochemistry and confocal microscopy analysis of the survivin splice variants in breast cancer tissues: survivin
(A, D), Survivin-ΔEx3 (B,E), and Survivin-2B (C,F). The receptor status (ER + PR + Her2-) (A-C), and (ER + PR-Her+) (D-F). Original magnification is
20X. (ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth receptor type 2; α, antibody).
Khan et al. BMC Cancer 2014, 14:176 Page 7 of 9
http://www.biomedcentral.com/1471-2407/14/176antagonist [23,24] against the function of Survivin and/or
Survivin-ΔEx3. If successful, Survivin-2B could be con-
firmed as a good prognostic marker in this disease. We
will need to follow this up with a larger patient population.
In late stage breast cancer (Stage IV), with visceral organ
or bone metastasis, expression of Survivin-2B in both tu-
mors as well as in exosomes was low to absent. This may
indicate an unfavorable role of Survivin-2B in breast can-
cer development and thus therapeutic efficiency may beFigure 4 Immuno-confocal microscopy of survivin splice variants in b
(ER-PR-Her2-), and double positive, single negative (ER + PR + Her2-) breast
Survivin-2B antibodies (B, D, F). Original magnification is 20X.enhanced by increasing Survivin-2B expression. Differen-
tial endogenous expression of Survivin, Survivin-ΔEx3,
and Survivin-2B is reported in different cancers including
breast cancers [6,9,25-27]. Although Ryan et al., reported
that levels of both survivin-2B and survivin-ΔEx3 but not
survivin were significantly higher in nodal metastases than
primary carcinomas [6], we found the opposite in our tis-
sue and exosomes with regard to Survivin variant proteins.
Survivin and Survivin-ΔEx3 were the predominant formsreast cancer tissues. Triple positive (ER + PR + Her2+), triple negative
cancer tissues were immune-stained with Survivin (A, C, E), and
Figure 5 Immuno-confocal microscopy of survivin splice variants in breast cancer tissues. Survivin and Survivin-ΔEx3 expression are shown
to colocalize in higher grades of breast tumor tissues (A-C) and distant (bone) metastasis (D-E). Colocalization was shown when both stainings
are superimposed as a yellow pattern (C and F). Original magnification is 20X.
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ference was particularly marked for Survivin-2B and may
relate to the fact that by the advent of commercially avail-
able antibodies, we were able to identify different isoforms
precisely in both exosomes and cancer tissues in this
study. Therefore, it is desirable to detect each of the Survi-
vin splice variant proteins and mRNA to determine breast
cancer prognosis.
Conclusion
In conclusion, exosomal Survivin and the Survivin splice
variant expression patterns mimic that found in tumor
tissue and thus may prove promise as tumor markers in
the early detection of breast cancer. Also, we found that
there is an inverse relationship between the staging of
the breast cancer and expression of Survivin-2B, i.e., in
the early stage when Survivin-2B is available patients are
likely to have a favorable treatment outcome. In the later
stages of the disease, constant expression of Survivin
and Survivin-ΔEx3 throughout the disease stages may
indicate an aggressive phenotype. Therefore, from a can-
cer prevention and therapeutics point of view, Survivin-
2B, which is a proapoptotic protein [6], may act as a
natural antagonist against the function of Survivin and/
or Survivin-ΔEx3 leading to novel approaches for cancer
prevention and/or therapeutics through differential mo-
dulation of the expression of Survivin and/or its variants.
Although data from several reports suggest a potential role
of Survivin-2B in countering the function of Survivin and/
or Survivin-ΔEx3 in tumor development, much more
needs to be done before deriving a definitive conclusion.Further study is underway in our lab to confirm the role
of Survivin-2B as a breast cancer prognostic marker in a
large cohort of breast cancer patients.
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